When used for previously treated EGFR T790M mutation‐positive NSCLC, osimeritinib increased median PFS from 4.4 months in chemotherapy to 10.1 months in osimeritinib (HR, 0.30; 95%CI: 0.23, 0.41; p < 0.001), ORR from 29 to 65%. This evidence concerns the gene EGFR and non-small cell lung carcinoma.